| Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression R Salpini, L Colagrossi, MC Bellocchi, M Surdo, C Becker, C Alteri, ... Hepatology 61 (3), 823-833, 2015 | 136 | 2015 |
| Emerging patterns and implications of HIV-1 integrase inhibitor resistance AM Geretti, D Armenia, F Ceccherini-Silberstein Current opinion in infectious diseases 25 (6), 677-686, 2012 | 98 | 2012 |
| Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels MM Santoro, L Fabeni, D Armenia, C Alteri, D Di Pinto, F Forbici, A Bertoli, ... Clinical infectious diseases 58 (8), 1156-1164, 2014 | 81 | 2014 |
| Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing D Armenia, I Vandenbroucke, L Fabeni, H Van Marck, V Cento, R D’Arrigo, ... Journal of Infectious Diseases 205 (4), 557-567, 2012 | 72 | 2012 |
| Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors F Ceccherini-Silberstein, K Van Baelen, D Armenia, M Trignetti, ... Antimicrobial agents and chemotherapy 54 (9), 3938-3948, 2010 | 57 | 2010 |
| Impact of pre-therapy viral load on virological response to modern first-line HAART MM Santoro, D Armenia, C Alteri, P Flandre, A Calcagno, M Santoro, ... Antiviral therapy 18 (7), 867-876, 2013 | 48 | 2013 |
| The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype I Malet, S Fourati, C Charpentier, L Morand-Joubert, D Armenia, M Wirden, ... Journal of Antimicrobial Chemotherapy 66 (12), 2827-2830, 2011 | 47 | 2011 |
| Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA M Zaccarelli, MM Santoro, D Armenia, V Borghi, W Gennari, C Gori, ... Journal of Clinical Virology 82, 94-100, 2016 | 40 | 2016 |
| Multiple hepatitis B virus (HBV) quasispecies and immune-escape mutations are present in HBV surface antigen and reverse transcriptase of patients with acute hepatitis B M Aragri, C Alteri, A Battisti, D Di Carlo, C Minichini, C Sagnelli, ... The Journal of infectious diseases 213 (12), 1897-1905, 2016 | 37 | 2016 |
| HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia D Armenia, L Fabeni, C Alteri, D Di Pinto, D Di Carlo, A Bertoli, C Gori, ... Journal of Antimicrobial Chemotherapy 70 (6), 1865-1873, 2015 | 29 | 2015 |
| The lowest X4 Geno2Pheno false‐positive rate is associated with greater CD4 depletion in HIV‐1 infected patients MM Santoro, D Armenia, L Fabeni, M Santoro, C Gori, F Forbici, V Svicher, ... Clinical Microbiology and Infection 18 (8), E289-E298, 2012 | 26 | 2012 |
| Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy C Soulie, MM Santoro, A Storto, B Abdi, C Charpentier, D Armenia, A Jary, ... Journal of Antimicrobial Chemotherapy 75 (4), 1026-1030, 2020 | 23 | 2020 |
| Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment D Armenia, M Zaccarelli, V Borghi, W Gennari, D Di Carlo, A Giannetti, ... Journal of Clinical Virology 104, 61-64, 2018 | 22 | 2018 |
| The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing V Svicher, V Cento, G Rozera, I Abbate, MM Santoro, D Armenia, ... PLoS One 8 (1), e53603, 2013 | 20 | 2013 |
| Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and-treated patients I Malet, M Wirden, S Fourati, D Armenia, B Masquelier, L Fabeni, S Sayon, ... Journal of antimicrobial chemotherapy 66 (7), 1481-1483, 2011 | 20 | 2011 |
| Virological response and resistance in multi-experienced patients treated with raltegravir F Ceccherini-Silberstein, D Armenia, R D'Arrigo, V Micheli, L Fabeni, ... ANTIVIRAL THERAPY 13 (4), A20-A20, 2008 | 20 | 2008 |
| Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children J Fokam, MC Bellocchi, D Armenia, AJ Nanfack, L Carioti, F Continenza, ... Medicine 97 (13), e0176, 2018 | 18 | 2018 |
| Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES study MM Santoro, D Armenia, E Teyssou, JR Santos, C Charpentier, ... Journal of Global Antimicrobial Resistance 31, 52-62, 2022 | 17 | 2022 |
| Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database F Lombardi, A Giacomelli, D Armenia, A Lai, A Dusina, A Bezenchek, ... International journal of antimicrobial agents 57 (2), 106252, 2021 | 17 | 2021 |
| Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single … D Armenia, D Di Carlo, A Calcagno, G Vendemiati, F Forbici, A Bertoli, ... Journal of Antimicrobial Chemotherapy 72 (3), 855-865, 2017 | 17 | 2017 |
